In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens

被引:36
作者
Johnson, EM [1 ]
Szekely, A [1 ]
Warnock, DW [1 ]
机构
[1] Publ Hlth Lab Serv, Mycol Ref Lab, Bristol BS2 8EL, Avon, England
关键词
D O I
10.1128/AAC.43.5.1260
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The in vitro activity of Syn-2869 was compared with that of amphotericin B and itraconazole. MICs for 100 isolates of pathogenic molds belonging to 12 species were determined by a broth microdilution adaptation of the method recommended by the National Committee for Clinical Laboratory Standards. Syn-2869 and itraconazole showed comparable, good activity against the dematiaceons molds Cladophialophora bantiana, Cladophialophora carrionii, Exophiala dermatitidis, Fonsecaea pedrosoi, Phialophora parasitica, and Ramichloridium mackenziei. Neither of the azole agents was active against the hyaline molds Fusarium solani, Scedosporium prolificans, and Scopulariopsis brevicaulis, but both were more active than amphotericin B against Scedosporium apiospermum. The MICs of the three agents were comparable for the mucoraceous mold Absidia corymbifera, but Syn-2869 appeared to be the least active against the dimorphic mold Sporothrix schenckii. Our results suggest that Syn-2869 could be effective against a range of mold infections in humans.
引用
收藏
页码:1260 / 1263
页数:4
相关论文
共 30 条
  • [1] ABEL MD, 1998, 38 INT C ANT AG CHEM, P270
  • [2] ANAISSIE E, 1992, CLIN INFECT DIS S1, V14, P43
  • [3] Deep infections caused by Scedosporium prolificans - A report on 16 cases in Spain and a review of the literature
    Berenguer, J
    RodriguezTudela, JL
    Richard, C
    Alvarez, M
    Sanz, MA
    Gaztelurrutia, L
    Ayats, J
    MartinezSuarez, JV
    [J]. MEDICINE, 1997, 76 (04) : 256 - 265
  • [4] Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection
    Denning, DW
    Radford, SA
    Oakley, KL
    Hall, L
    Johnson, EM
    Warnock, DW
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) : 401 - 414
  • [5] NIAID MYCOSES STUDY-GROUP MULTICENTER TRIAL OF ORAL ITRACONAZOLE THERAPY FOR INVASIVE ASPERGILLOSIS
    DENNING, DW
    LEE, JY
    HOSTETLER, JS
    PAPPAS, P
    KAUFFMAN, CA
    DEWSNUP, DH
    GALGIANI, JN
    GRAYBILL, JR
    SUGAR, AM
    CATANZARO, A
    GALLIS, H
    PERFECT, JR
    DOCKERY, B
    DISMUKES, WE
    STEVENS, DA
    [J]. AMERICAN JOURNAL OF MEDICINE, 1994, 97 (02) : 135 - 144
  • [6] In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
    Espinel-Ingroff, A
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (01) : 198 - 202
  • [7] Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
    Espinel-Ingroff, A
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) : 2950 - 2956
  • [8] Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi
    EspinelIngroff, A
    Bartlett, M
    Bowden, R
    Chin, NX
    Cooper, C
    Fothergill, A
    McGinnis, MR
    Menezes, P
    Messer, SA
    Nelson, PW
    Odds, FC
    Pasarell, L
    Peter, J
    Pfaller, MA
    Rex, JH
    Rinaldi, MG
    Shankland, GS
    Walsh, TJ
    Weitzman, I
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (01) : 139 - 143
  • [9] FOTHERGILL AW, 1998, 38 INT C ANT AG CHEM, P484
  • [10] FURUKAWA T, 1998, 38 INT C ANT AG CHEM, P270